Global Metabolomic Analysis Research Articles

Benzo(a)anthracene Targeting SLC1A5 to Synergistically Enhance PAH Mixture Toxicity.

Human exposure to polycyclic aromatic hydrocarbons (PAHs) as mutagenic and carcinogenic pollutants in the environment often occurs in the form of mixtures. Although the mixture effects of PAHs have been previously recognized, the toxicological mechanisms to explain them still remain quite unclear. This study combined metabolomics and chemical proteomics methods to comprehensively understand the mixture effects of a PAH mixture including benzo(a)anthracene (BaA), benzo(b)fluoranthene (BbF), benzo(a)pyrene (BaP), and chrysene (CHR). Among them, BaA has shown a strong synergistic effect with other PAHs. Interestingly, BaA alone is not a potent oxidative stress inducer in liver cells but dose-dependently amplifies oxidative damage caused by the PAH mixture. Global metabolomics analysis results revealed damage to the antioxidant glutathione synthesis, which was caused by the glutamine depletion caused by BaA in the mixture. Subsequently, the label-free chemical proteomics and cellular thermal shift analysis (CETSA) demonstrated that the PAH mixture altered the thermal shift of glutamine transporter SLC1A5. Furthermore, Western blotting and the isothermal titration calorimetry (ITC) interaction measurements showed nanomolar KD values between BaA and SLC1A5. Overall, this study showed that BaA synergistically contributed to PAH mixture induced oxidative damage by targeting SLC1A5 to inhibit glutamate transport into cells, resulting in the inhibition of glutathione synthesis.

Exploration of potential biomarkers for prurigo nodularis based on plasma-metabolome analysis.

Prurigo nodularis (PN) is a chronic and debilitating skin disease with severe itching that negatively impacts patients' quality of life and mental state. However, the treatment options for PN remain limited. Global metabolomics analysis can offer effective information on energy metabolism, pathogenesis and potential diagnostic biomarkers. No study on metabolomic analysis of PN has been reported. To further understand the mechanisms of PN and analyse the plasma metabolite profiles in patients with PN. Targeted-metabolome analysis of 306 metabolites in plasma from 18 patients with PN and 19 healthy controls was performed using Liquid Chromatography-tandem Mass Spectrometer analysis. We identified 31 differential metabolites. Most acylcarnitines, long-chain fatty acids, alpha-aminobutyric acid, hydroxybutyric acid and lactic acid among these metabolites were up-regulated in patients with PN; in contrast, glucaric acid, suberic acid, bile acid derivatives and most amino acids were down-regulated. Positive correlations exist between glucaric acid and itching severity and acylcarnitines and insomnia. Suberic acid and the Investigator's Global Assessment (IGA) scores correlate negatively. Metabolite variation reflects the dysregulation of energy metabolism and chronic systematic inflammation in PN. Several metabolites, such as glucaric acid, suberic acid and acylcarnitines, merit further study as potential biomarkers of disease severity in PN.

Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis.

Mortality rates due to lung cancer are high worldwide. Although PD-1 and PD-L1 immune checkpoint inhibitors boost the survival of patients with non-small-cell lung cancer (NSCLC), resistance often arises. The Warburg Effect, which causes lactate build-up and potential lysine-lactylation (Kla), links immune dysfunction to tumor metabolism. The role of non-histone Kla in tumor immune microenvironment and immunotherapy remains to be clarified. Here, global lactylome profiling and metabolomic analyses of samples from patients with NSCLC is conducted. By combining multi-omics analysis with in vitro and in vivo validation, that intracellular lactate promotes extracellular lipolysis through lactyl-APOC2 is revealed. Mechanistically, lactate enhances APOC2 lactylation at K70, stabilizing it and resulting in FFA release, regulatory T cell accumulation, immunotherapy resistance, and metastasis. Moreover, the anti-APOC2K70-lac antibody that sensitized anti-PD-1 therapy in vivo is developed. This findings highlight the potential of anti lactyl-APOC2-K70 approach as a new combination therapy for sensitizing immunotherapeutic responses.

Physiological, biochemical, and global transcriptomic and metabolomic analyses of the effect of the antifungal compound isobavachalcone on Botrytis cinerea on cherry tomatoes

Botrytis cinerea is a major postharvest pathogen on cherry tomato (Solanum lycopersicum). In this study, isobavachalcone (IBC) exhibited inhibitory activity against fungus B. cinerea in vitro and in vivo. Morphological and ultrastructural observations were conducted revealing that IBC caused significant changes in B. cinerea, including rupturing of the cell membrane, loosening of the cell wall, swelling of mitochondria, and massive reductions in the number of ribosomes. Physiological and biochemical analyses confirmed that IBC increased the permeability of the cell wall and membrane which had led to decrease in mitochondrial membrane potential (MMP), while significant increase in reactive oxygen species (ROS) level. According to transcriptomic and metabolomic analysis, IBC inhibited the expression of chitin deacetylase (CDA), glucan 1,3-beta-glucosidase (EXG), and squalene monooxygenase (ERG1) genes, which may result in the degradation of cell wall and membrane components, ultimately increasing cell permeability. IBC also interfered with the expression of cytochrome P450 (CYP102A) and cytochrome-b5 reductase (CYB5R) genes, which had a negative impact on mitochondrial energy metabolism. Additionally, the structure of the ribosomal large subunit and small subunit were altered by IBC, thus, interfering with translation initiation and polypeptide extension. These results provide an effective alternative approach against B. cinerea on cherry tomato.

Metabolomics reveals the lipid metabolism disorder in Pelophylax nigromaculatus exposed to environmentally relevant levels of microcystin-LR

Cyanobacterial blooms have emerged as a significant environmental issue worldwide in recent decades. However, the toxic effects of microcystin-LR (MC-LR) on aquatic organisms, such as frogs, have remained poorly understood. In this study, frogs (Pelophylax nigromaculatus) were exposed to environmentally relevant concentrations of MC-LR (0, 1, and 10 μg/L) for 21 days. Subsequently, we assessed the impact of MC-LR on the histomorphology of the frogs' livers and conducted a global MS-based nontarget metabolomics analysis, followed by the determination of substances involved in lipid metabolism. Results showed that MC-LR significantly induced histological alterations in the frogs' hepatopancreas. Over 200 differentially expressed metabolites were identified, primarily enriched in lipid metabolism. Biochemical analysis further confirmed that MC-LR exposure led to a disorder in lipid metabolism in the frogs. This study laid the groundwork for a mechanistic understanding of MC-LR toxicity in frogs and potentially other aquatic organisms.

Analysis of Metabolic Changes in Endogenous Metabolites and Diagnostic Biomarkers for Various Diseases Using Liquid Chromatography and Mass Spectrometry.

Analysis of endogenous metabolites in various diseases is useful for searching diagnostic biomarkers and elucidating the molecular mechanisms of pathophysiology. The author and collaborators have developed some LC/tandem mass spectrometry (LC/MS/MS) methods for metabolites and applied them to disease-related samples. First, we identified urinary conjugated cholesterol metabolites and serum N-palmitoyl-O-phosphocholine serine as useful biomarkers for Niemann-Pick disease type C (NPC). For the purpose of intraoperative diagnosis of glioma patients, we developed the LC/MS/MS analysis methods for 2-hydroxyglutaric acid or cystine and found that they could be good differential biomarkers. For renal cell carcinoma, we searched for various biomarkers for early diagnosis, malignancy evaluation and recurrence prediction by global metabolome analysis and targeted LC/MS/MS analysis. In pathological analysis, we developed a simultaneous LC/MS/MS analysis method for 13 steroid hormones and applied it to NPC cells, we found 6 types of reductions in NPC model cells. For non-alcoholic steatohepatitis (NASH), model mice were prepared with special diet and plasma bile acids were measured, and as a result, hydrophilic bile acids were significantly increased. In addition, we developed an LC/MS/MS method for 17 sterols and analyzed liver cholesterol metabolites and found a decrease in phytosterols and cholesterol synthetic markers and an increase in non-enzymatic oxidative sterols in the pre-onset stage of NASH. We will continue to challenge themselves to add value to clinical practice based on cutting-edge analytical chemistry methodology.

Abstract P311: Metabolomic Associations With Blood Pressure and Hypertension in Multi-Ethnic Populations

Introduction: Hypertension (HTN) is a leading cause of cardiovascular disease and premature death. A few circulating metabolites have been associated with blood pressure or HTN; however, findings from multi-ethnic populations are limited. Methods: Discovery analysis included eight population-based cohorts from the Trans-Omics for Precision Medicine (TOPMed) consortium, including adults of White, Black and Hispanic/Latino ancestries. Replication analyses were performed in six independent studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) and TOPMed. Fixed-effect inverse variance weighted meta-analysis was applied, on study- and ethnic-specific linear and logistic regression results, to estimate circulating metabolites association with systolic (SBP), diastolic blood pressure (DBP), and HTN cross-sectionally, adjusting for age, sex, body mass index, smoking status, lipids, kidney function, and diabetes prevalence. Global metabolomic analysis and pathway enrichment were performed to identify potentially altered metabolic pathways, and two-sample Mendelian randomization (MR) was performed to test for causal relationships between replicated metabolites and SBP, DBP, and HTN. Results: Out of 1,055 meta-analyzed metabolites, 336 were significantly associated (FDR&lt0.05) with all three BP traits among 17,767 participants (7,097 White, 5,406 Black, and 5,264 Hispanic/Latino). Xanthopterin had the strongest positive association (SBP: β=3.16, DBP: β=1.78, HTN: OR=1.34), and NH4_C18:2 CE had the strongest inverse association (SBP: β=-2.31, DBP: β=-1.49, HTN: OR=0.75), per SD increase of the metabolite level. The directions of associations were generally consistent across sex and racial/ethnic groups. Pathway enrichment analysis identified two enriched pathways (FDR&lt0.05): alanine, aspartate and glutamate metabolism and citrate cycle. Of 222 metabolites available for replication, 114 metabolites associated with all three traits (FDR&lt0.05) among 20,567 participants. MR analysis identified 18 potentially causal associations between metabolites and BP traits, including palmitoylcarnitine - a carnitine derivative that showed consistent positive causal associations across SBP, DBP and HTN (FDR&lt0.05).

Untargeted metabolomics unveiled the role of butanoate metabolism in the development of Pseudomonas aeruginosa hypoxic biofilm.

Pseudomonas aeruginosa is a versatile opportunistic pathogen which causes a variety of acute and chronic human infections, some of which are associated with the biofilm phenotype of the pathogen. We hypothesize that defining the intracellular metabolome of biofilm cells, compared to that of planktonic cells, will elucidate the metabolic pathways and biomarkers indicative of biofilm inception. Disc-shaped stainless-steel coupons (12.7 mm diameter) were employed as a surface for static biofilm establishment. Each disc was immersed in a well, of a 24-well microtiter plate, containing a 1-mL Lysogeny broth (LB) suspension of P. aeruginosa ATCC 9027, a strain known for its biofilm prolificacy. This setup underwent oxygen-depleted incubation at 37°C for 24 hours to yield hypoxic biofilms and the co-existing static planktonic cells. In parallel, another planktonic phenotype of ATCC 9027 was produced in LB under shaking (200 rpm) incubation at 37°C for 24 hours. Planktonic and biofilm cells were harvested, and the intracellular metabolites were subjected to global untargeted metabolomic analysis using LC-MS technology, where small metabolites (below 1.5 kDa) were selected. Data analysis showed the presence of 324 metabolites that differed (p < 0.05) in abundance between planktonic and biofilm cells, whereas 70 metabolites did not vary between these phenotypes (p > 0.05). Correlation, principal components, and partial least square discriminant analyses proved that the biofilm metabolome is distinctly clustered away from that of the two planktonic phenotypes. Based on the functional enrichment analysis, arginine and proline metabolism were enriched in planktonic cells, but butanoate metabolism was enriched in biofilm cells. Key differential metabolites within the butanoate pathway included acetoacetate, 2,3-butandiol, diacetyl, and acetoin, which were highly upregulated in the biofilm compared to the planktonic cells. Exogenous supplementation of acetoin (2 mM), a critical metabolite in butanoate metabolism, augmented biofilm mass, increased the structural integrity and thickness of the biofilm, and maintained the intracellular redox potential by balancing NADH/NAD+ ratio. In conclusion, P. aeruginosa hypoxic biofilm has a specialized metabolic landscape, and butanoate pathway is a metabolic preference and possibly required for promoting planktonic cells to the biofilm state. The butanoate pathway metabolites, particularly acetoin, could serve as markers for biofilm development.

Non-target influence of imidacloprid residues on grape global metabolome and berry quality with the identification of metabolite biomarkers.

This paper illustrates the non-target impact of imidacloprid (IM) residues on the grape global metabolome and biomarker identification with high-resolution mass spectrometry. IM was applied at the recommended dose (SD), and ten times SD (10 RD). The global metabolome analysis revealed that 21 metabolites were up- and down-regulated with IM SD treatment. In 10 RD, 9 metabolites were upregulated, and 28 were downregulated. Pathway enrichment analysis revealed the primary and secondary pathway disruption in grapes. Berry quality was affected with decrease in flavonoids by 32.97% in 10 RD; phenols were reduced by 53.93 in SD, 50.8% in 10 RD. The non-target and target study revealed the degradation of IM in grapes to desnitro-IM and IM-urea which were identified as a potential biomarker for IM residues in grapes, which would benefit the authentication of organic product. Overall, imidacloprid showed a significant impact on the grape metabolome and quality.

Abstract B061: Development of a pancreatic ductal adenocarcinoma 3D tumor model for high-throughput drug screening

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a persistent malignancy that is difficult to diagnose in its early stage and is one of the leading cancer-related deaths worldwide. Currently, limited therapeutic options are available for PDAC, resulting in an extremely low 5-year survival rate. To speed up the discovery of novel therapeutics, a reliable 3D model that highly simulates the PDAC tumor microenvironment is needed for large-scale drug screening. In this study, we propose a novel 3D model for restoring the PDAC tumor microenvironment by targeting cancer-associated fibroblasts (CAFs), which serve as the key component of the PDAC, providing its heterogeneity and contributing to reciprocal signaling and drug resistance. Our previous studies have demonstrated that Adipose-derived mesenchymal stem cells can differentiate into varying subtypes CAFs when co-cultured with PDAC cells both in vitro and in vivo. Following this strategy, we utilize the fibroblast-populated collagen lattice (FPCL) modeling approach, which relies on the contractility of fibroblasts in a collagen gel matrix, to provide the mechanical stress and hypoxic conditions for the 3D tumor models. Human Adipose-derived mesenchymal stem cells as CAF precursors and PDAC cell lines were mixed with collagen solution to make the collagen discs, resulting in the formation of 3D PDAC tumor models within a week. The morphological analyses, along with global transcriptome and metabolomic analyses, were performed to confirm the clinical-like mature ductal glands of PDAC cells and CAFs-like spindle-shaped of mesenchymal stem cells in the interior of PDAC-FPCL (PDAC-F). Moreover, the PDAC-F has shown a high tumorigenic potential in vivo animal model. Additionally, PDAC-F was shown to allow combination therapies screening of anticancer and antifibrotic drugs in the drug screening test, demonstrating that the combination therapeutics have better efficacy. In conclusion, our PDAC-F is built with distinct features of PDAC, reproducing the heterogeneous and high stiffness with a clinical-like PDAC morphology. In addition, the short modeling time and the high reproducibility of this PDAC-F open the possibilities for large-scale drug screening, which is expected to accelerate new drug development and provide effective treatment for pancreatic cancer patients. Citation Format: Xiaoyu Song, Yuma Nihashi, Yasuyuki S. Kida. Development of a pancreatic ductal adenocarcinoma 3D tumor model for high-throughput drug screening [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr B061.

Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation: A Feasibility Study

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is limited by acute graft versus host disease (GVHD). GVHD is the principal cause of non-relapse mortality (NRM) and a major cause of morbidity after allo-HCT. Recent published experimental data demonstrated that altering the microbiome-metabolite axis regulates acute GVHD severity. Specifically, short chain fatty acid (SCFA) butyrate was significantly decreased in the intestinal epithelial cells (IECs) of mice experiencing GVHD, while restoring butyrate levels by increasing intestinal butyrate-producing bacteria, reduced experimental acute GI GVHD severity and mortality. Prebiotics usually refer to indigestible carbohydrates that are metabolized by the intestinal microbiota to produce microbial metabolites, such as SCFAs, that serve as nutrients for IECs. Administration of defined quantities of resistant potato starch (RPS), as a prebiotic, to normal healthy human volunteers promoted increase in butyrogenic bacteria and increased intestinal levels of SCFA butyrate to a greater extent than other commercially available resistant starch preparations tested. These data form the rationale for this study and led to prospectively study the clinical feasibility and impact of the administration of RPS as a prebiotic dietary intervention on the intestinal microbiota and its dependent metabolites in allo-HCT recipients. Adults undergoing human leukocyte antigen-matched, related-donor myeloablative allo-HCT were recruited and received RPS orally daily from day -7 to day 100 after allo-HCT. Stool samples were collected in the OMNIgene-Gut® (DNA Genotek) collection kit. Fecal samples were subjected to 16S rRNA gene sequencing to determine microbiota composition and quantification of fecal SCFAs was performed by liquid chromatography. Blood specimens were collected using standardized protocols. The effect of RPS on plasma SCFAs and &amp;gt; 200 other metabolites was longitudinally assessed using targeted and global metabolomic analyses. Mass spectrometry was utilized for quantification of plasma metabolites. The primary objective was to assess the feasibilty and test the effect of RPS on the structure of the patients' intestinal microbiome. Metrics for the feasibility of this dietary intervention were prespecified by setting a target for ≥ 60 % of patients to adhere to ≥ 70% of scheduled doses. We hypothesized that RPS would be feasible and increase stool butyrate levels as a byproduct of microbial metabolism. Key secondary objectives were to longitudinally evaluate plasma metabolites in recipients of RPS compared to historical controls as well as assess tolerability of RPS in allo-HCT recipients. Ten subjects were enrolled. The primary endpoint was met. Feasibility exceeded the preset goal of ≥ 70% adherence to scheduled dosages in ≥ 60 % of patients as 8 of the 10 patients (80%) received ≥ 70 % of scheduled doses. Intestinal butyrate levels were significantly higher while participants were on RPS as compared to when they were not on RPS (p &amp;lt; 0.0001) (fig. 1A). We observed longitudinal changes in plasma metabolites post allo-HCT compared to baseline independent of whether allo-HCT recipients received RPS (p &amp;lt; 0.0001) (fig. 1B). In RPS recipients, the dominant plasma metabolites were, however, much more stable across timepoints when compared to historic controls suggesting a greater equilibrium in their production and consumption (fig. 1C). The median age of participants was 57 years (range 52-62 years). All subjects received standard GVHD prophylaxis with tacrolimus and methotrexate as well as standard antibiotic prophylaxis with levaquin, and standard neutropenic fever treatment with IV cefepime (90%) or IV vancomycin, No adverse effects/toxicities attributed to RPS were observed and longitudinal specimens were collected successfully (table 1). This study showed that a dietary intervention using RPS in allo-HCT recipients is feasible, and was able to rationally alter the salutary intestinal microbial metabolite SCFA butyrate, despite the utilization of several HCT related medications, including antibiotics. These data demonstrate translation of fundamental discoveries in mouse allo-HCT studies, to testing RPS in healthy humans, to showing that RPS is a feasible microbiome-modifying intervention in allo-HCT recipients, and that a prebiotic strategy can now be applied and tested to mitigate acute GVHD in allo-HCT.

Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML

Venetoclax (anti-BCL2) is approved for elderly patients with acute myeloid leukemia (AML) in combination with hypomethylating agents such as azacitidine or decitabine. However, several resistance mechanisms arise, impeding responses in patients. These resistance mechanisms include TP53 or FLT3-ITD mutations, suppression of pro-apoptotic proteins NOXA or PUMA, increases in oxidative phosphorylation and energy metabolism, or elevated expression of S100A8/A9. Recent reports have highlighted that hyperactivation of the integrated stress response (ISR) pathway overcomes venetoclax resistance through NOXA activation and glycolytic activity inhibition. However, these studies used drugs that indirectly activate the ISR with other off-target effects. General Control Nonderepressible 2 (GCN2) is an ISR kinase that senses and responds to nutrient stress conditions, and activation of GCN2 results in antitumor activity. We are developing HC-7366, a first-in-class, first-in-human direct GCN2 activator, and are currently evaluating this agent in a phase 1 clinical trial in solid tumors (NCT05121948). Here we present a series of studies characterizing the antitumor effects of HC-7366 in AML, and how it impacts venetoclax resistance. AML patients with TP53 mutations are known to have lower response rates to venetoclax.The in vivo efficacy of HC-7366 in both CDX and PDX models was independent of TP53 mutation, resulting in 100% complete response and 100% tumor growth inhibition in TP53-mutated MOLM-16 and KG-1 tumor models, respectively. Analysis of tumors from treated mice by IHC demonstrated activation of the ISR as evidenced by increased expression of the ATF4 targets ASNS and PSAT1. A genome-wide CRISPR screen in KG-1 cells revealed that GCN2 sgRNAs were significantly enriched in HC-7366-treated cells, highlighting the importance of GCN2 activation in mediating the mechanism of action of HC-7366. Interestingly, BCL2 sgRNAs were significantly depleted in HC-7366 treated cells, suggesting a synthetic lethal relationship with BCL2 inhibitors, such as venetoclax, when combined with HC-7366. Indeed, in the MV4-11 FLT3-ITD mutant model (a differentiated subtype of AML that shows limited response to venetoclax), the combination of HC-7366 and venetoclax produced substantial benefit resulting in 26% tumor regression and enhanced activation of the ISR pathway. HC-7366 treatment also increased mRNA and protein levels of NOXA and PUMA while reducing mitochondrial respiration and glycolysis in a GCN2-dependent manner, leading to a low energetic state. Consistent with its impact on cellular energetics, global metabolomic analyses of AML xenograft tumors showed that HC-7366 significantly altered metabolites associated with glycolysis and the TCA cycle. Additionally, HC-7366 reduced protein levels of S100A8/A9, also known to correlate with venetoclax resistance. Our in vitro and in vivo results demonstrate that HC-7366 is a potent GCN2 activator with strong antitumor activity in AML as a single agent and in combination with venetoclax. The potential of HC-7366 to counteract multiple known resistance mechanisms to venetoclax could provide a viable treatment option for patients with relapsed/refractory AML when used in combination with venetoclax.

242 Methionine and Guanidinoacetic Acid Supplementation During the Periconceptual Period of Gestation Shifts Methionine Metabolism of Fetal Bull Calves at D 63 of Gestation

Abstract Recent research has demonstrated that feeding rumen protected methionine (MET) products increases circulating methionine while feeding guanidinoacetic acid (GAA) may result in a methyl deficiency. Therefore, we hypothesized that maternal MET or GAA supplementation from 63 days before breeding until d 63 of gestation would increase fetal hepatic methyl donors or result in a fetal hepatic methyl donor deficiency, respectively. Eighty MARC II heifers (n = 20 per treatment; initial BW = 344 ± 8 kg; day -63) were weighed and assigned to one of four breeding groups and four treatments stratified by age and starting weight. Heifers were fed a total mixed ration to gain 0.68 kg/d and received 100 g of one of four treatments top dressed: control supplement of ground corn (CON), MET (10 g/d) in a ground corn carrier, GAA (40 g/d) in a ground corn carrier, or MET + GAA (10 g/d MET + 40 g/d GAA) in a ground corn carrier. At breeding (d 0), all heifers were bred to a single sire using male sexed semen. At d 63 of gestation, 35 heifers (CON n = 10, MET n = 8, GAA n = 7, MET + GAA, n = 10) confirmed pregnant with bull calves were humanely slaughtered and fetal liver tissues were collected and sent to Metabolon Inc. for global metabolomics analysis. Data were analyzed as a 2 x 2 factorial with 2 levels of GAA and 2 levels of MET with breeding group included in the model. For this abstract, only metabolites from the methionine cycle and adjacent pathways will be reported and only metabolites with significant P-values will be discussed (P ≤ 0.05). There were no main effects or interactions for the abundance of methionine, GAA, creatine, SAM, SAH or homocysteine. Glycine was decreased and sarcosine increased in fetuses from MET supplemented dams. Serine was affected by a MET x GAA interaction being decreased in livers of CON, MET, and MET + GAA fetuses compared with GAA. Cystathione, S-methylcysteine, s-methylcysteine sulfoxide, and hypotaurine were greater in fetuses of MET supplemented heifers and pyridoxal phosphate was reduced in fetal liver of MET supplemented heifers. The abundance of urea was greater in GAA supplemented fetuses. These results indicate that fetuses from dams fed methionine may be able to maintain balance in methionine supply by shunting methionine through adjacent pathways including the transsulfuration pathway. We also interpret these data to imply that excess methionine is not utilized by the fetus and is metabolized to products that can be excreted. Lastly, GAA did not alter the fetal methyl supply. USDA is an equal opportunity provider and employer. Funded by (USDA-NIFA-AFRI # 2022-67015-36196).

THU612 SDHx Pheochromocytoma/Paraganglioma Has Elevation Of Arginine And Lysine Metabolites

Abstract Disclosure: H.K. Ghayee: None. S. Richter: None. N. Bechmann: None. S. Kalavalapalli: None. G. Joy: None. Y. Xu: None. K. Cusi: None. A. Tischler: None. J.F. Powers: None. F. Beuschlein: None. M. Robledo: None. S. Fliedner: None. M. Quinkler: None. M. Fassnacht: None. H. Timmers: None. K. Pacak: None. G. Eisenhofer: None. T.J. Garrett: None. Background: Pheochromocytomas and paragangliomas are rare neuroendocrine tumors that arise from the chromaffin cells of the adrenal medulla or sympathetic/parasympathetic paraganglia respectively. There are more than 25 genetic drivers identified in these tumors. These genetic mutations are categorized into the three main clusters. However, cluster 1 and cluster 2 comprise most of the known genes. Within cluster 1, SDHx mutations are associated with aggressive disease. To better understand the metabolic signature of these tumors, our group performed untargeted metabolomics of over 200 pheochromocytomas and paraganglioma tissue samples. Methods: Frozen tissues were processed and sent to the University of Florida and analyzed in 2 batches. Analysis was conducted using liquid chromatography high-resolution mass spectrometry with full blinding and randomization. Raw data were converted to mzXML and then processed using MZmine to identify features. Blank feature filtering was conducted to filter noise and very low abundant features. Metabolite identification was first conducted with reference to an in-house retention time library of 1200 metabolites and further identification was conducted by searching the human metabolome database. Statistical analysis was performed in R. Results: Comparing cluster 1 vs cluster 2, we observed an overall increase in purine metabolites specifically adenine, AMP, GMP, UMP, CMP, cytidine, and dihydrothymine in cluster 2. Arginine metabolism was lower in cluster 2, specifically dimethylarginine, citrulline, and N-methyl-L-arginine. Comparing SDHx vs cluster 1, we observed an overall increase in arginine metabolism with ornithine, citrulline, N-acetyl-ornithine, proline and hydroxy-proline. We also observed an increase in lysine metabolism in SDHx vs cluster 1 with lysine, N-acetyl-lysine, cadaverine, glutarate, 2-hydroxyglutarte, 2-oxoglutarate, succinate and trimethyllysine all being elevated. A decrease in serotonin in SDHx compared to cluster 1 was seen. Conclusion: Global metabolomic analysis of pheochromocytomas and paragangliomas has uncovered important pathways that drive the metabolic functions depending on the gene cluster. Most notably, arginine and lysine metabolites were increased in SDHx tumors. Presentation: Thursday, June 15, 2023

Dendrimer nanotherapy targeting of glial dysfunction improves inflammation and neurobehavioral phenotype in adult female Mecp2-heterozygous mouse model of Rett syndrome.

Rett syndrome is an X-linked neurodevelopmental disorder caused by mutation of Mecp2 gene and primarily affects females. Glial cell dysfunction has been implicated in in Rett syndrome (RTT) both in patients and in mouse models of this disorder and can affect synaptogenesis, glial metabolism and inflammation. Here we assessed whether treatment of adult (5-6 months old) symptomatic Mecp2-heterozygous female mice with N-acetyl cysteine conjugated to dendrimer (D-NAC), which is known to target glia and modulate inflammation and oxidative injury, results in improved behavioral phenotype, sleep and glial inflammatory profile. We show that unbiased global metabolomic analysis of the hippocampus and striatum in adult Mecp2-heterozygous mice demonstrates significant differences in lipid metabolism associated with neuroinflammation, providing the rationale for targeting glial inflammation in this model. Our results demonstrate that treatment with D-NAC (10 mg/kg NAC) once weekly is more efficacious than equivalently dosed free NAC in improving the gross neurobehavioral phenotype in symptomatic Mecp2-heterozygous female mice. We also show that D-NAC therapy is significantly better than saline in ameliorating several aspects of the abnormal phenotype including paw clench, mobility, fear memory, REM sleep and epileptiform activity burden. Systemic D-NAC significantly improves microglial proinflammatory cytokine production and is associated with improvements in several aspects of the phenotype including paw clench, mobility, fear memory, and REM sleep, and epileptiform activity burden in comparison to saline-treated Mecp2-hetereozygous mice. Systemic glial-targeted delivery of D-NAC after symptom onset in an older clinically relevant Rett syndrome model shows promise in improving neurobehavioral impairments along with sleep pattern and epileptiform activity burden. These findings argue for the translational value of this approach for treatment of patients with Rett Syndrome.

Abstract 040: Evidence Of Increased Glycolysis In Renal Cortex Of High Salt Fed Sprague Dawley Rats

To determine whole kidney O 2 and substance metabolism in an unanesthetized state, arterial (A), renal venous (Vr) blood and urine (U) were analyzed together with measurements of renal blood flow (RBF), blood pressure (BP) and GFR in conscious freely moving male SD rats. RBF and BP were measured continuously (24/7) via chronically implanted ultrasonic flow probe and A-line respectively. A and Vr blood through chronically implanted catheters and urine (U) were sampled intermittently when rats were fed a 0.4% NaCl (LS) diet and on days 7, 14, and 21 after switching to a 4.0% NaCl (HS) diet (HS7, HS14, HS21). A and Vr O 2 contents were determined by radiometer and a global metabolomic analysis was performed at the JAX Laboratory (LC-MS-MS). GFR was determined in another group of rats by transcutaneous detection of the attenuation of i.v. injected FITC sinistrin. Cortical (Cx) and outer medullary (OM) tissues were obtained from the other group of rats and underwent metabolomic and mRNAseq analyses (Novogene). From another group of rats, glomeruli (Glo), proximal tubules (PT) and non-PT were isolated for RT-PCR. BP and RBF slightly increased by HS3 (P&lt;0.05) and were sustained at these levels. O 2 extraction rose progressively from 0.10 ± 0.01 at LS to 0.14 ± 0.01 at HS21 (P&lt;0.05). GFR increased from 0.64 to 0.83 mL/min/100 g (P&lt;0.05) at HS7 and sustained. Na + reabsorption and O 2 consumption were positively correlated. Clear distinctions were observed in a sparse partial least squares discriminant analysis of tissue metabolomics among LS, HS14, and HS21. The mRNAseq analysis found that the HS diet resulted in the activation of immune system-related genes in both Cx and OM and the downregulation of genes related to the TCA cycle and metabolism of amino acids and fatty acids in Cx only. In contrast, glycolysis-related genes including hexokinase ( Hk ) and pyruvate kinase ( Pkm ) were upregulated in Cx. Metabolic fluxes (A-Vr-U) showed the increased release of lactate and pyruvate from the kidney when fed HS. Increased mRNA expression of Hk and Pkm in HS21 was observed only in PT but not in Glo and non-PT. In summary, SD rats fed a HS diet underwent changes in RBF, O 2 extraction, and utilization of substrates with evidence of increased glycolysis.

A global metabolomics minefield: Confounding effects of preanalytical factors when studying rare disorders.

A common challenge when studying rare diseases or medical conditions is the limited number of patients, usually resulting in long inclusion periods as well as unequal sampling and storage conditions. The main purpose of this study was to demonstrate the challenges when comparing samples subject to different preanalytical conditions. We performed a global (commonly referred to as "untargeted") liquid chromatography-high resolution mass spectrometry metabolomics analysis of blood samples from cases of sudden infant death syndrome and controls stored as dried blood spots on a chemical-free filter card for 15 years at room temperature compared with the same blood samples stored as whole blood at -80°C before preparing new dried blood spots using a chemically treated filter card. Principal component analysis plots distinctly separated the samples based on the type of filter card and storage, but not sudden infant death syndrome versus controls. Note that, 1263 out of 5161 and 642 out of 1587 metabolite features detected in positive and negative ionization mode, respectively, were found to have significant 2-fold changes in amounts corresponding to different preanalytical conditions. The study demonstrates that the dried blood spot metabolome is largely affected by preanalytical factors. This emphasizes the importance of thoroughly addressing preanalytical factors during study design and interpretation, enabling identification of real, biological differences between sample groups whilst preventing other factors or random variation to be falsely interpreted as positive results.

Global serum metabolomic and lipidomic analyses reveal lipid perturbations and potential biomarkers of the colorectal cancer by adenoma-carcinoma sequence

Global serum metabolomic and lipidomic analyses reveal lipid perturbations and potential biomarkers of the colorectal cancer by adenoma-carcinoma sequence

Global Metabolomics Analysis of Pakistani Citrus Cultivars Infected with Huanglongbing or Citrus Greening

Global Metabolomics Analysis of Pakistani Citrus Cultivars Infected with Huanglongbing or Citrus Greening

The acute effect of different NAD+ precursors included in the combined metabolic activators

NAD+ and glutathione precursors are currently used as metabolic modulators for improving the metabolic conditions associated with various human diseases, including non-alcoholic fatty liver disease, neurodegenerative diseases, mitochondrial myopathy, and age-induced diabetes. Here, we performed a one-day double blinded, placebo-controlled human clinical study to assess the safety and acute effects of six different Combined Metabolic Activators (CMAs) with 1 g of different NAD+ precursors based on global metabolomics analysis. Our integrative analysis showed that the NAD+ salvage pathway is the main source for boosting the NAD+ levels with the administration of CMAs without NAD+ precursors. We observed that incorporation of nicotinamide (Nam) in the CMAs can boost the NAD+ products, followed by niacin (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but not flush free niacin (FFN). In addition, the NA administration led to a flushing reaction, accompanied by decreased phospholipids and increased bilirubin and bilirubin derivatives, which could be potentially risky. In conclusion, this study provided a plasma metabolomic landscape of different CMA formulations, and proposed that CMAs with Nam, NMN as well as NR can be administered for boosting NAD+ levels to improve altered metabolic conditions.